Nine percent (11 out of 122) of malignant peripheral nerve sheath tumors showed retention of H3K27 trimethylation, as they demonstrated nuclear staining in 90% of the tumor cells (Figures 1f, g and 2f, 2g)
This isn't necessarily a disadvantage
The foundational and mechanistic evidence originates largely from one research group, independent corroboration is limited, and there is no robust placebo-controlled human trial measuring telomere length before and after administration
April 2026 Category 2 Update On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn
Oxidative stress is the real issue
This treatment is completely safe, and results can be seen after 24 hours